|Day Low/High||159.26 / 164.68|
|52 Wk Low/High||142.81 / 256.80|
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab)
We are not jumping up and down to put capital to work, but when we see things we like, we will buy them in increments.
We'll take advantage of this opportunity to buy on weakness with our healthy cash position.
President Trump made a long-awaited announcement of his administration's opioid plan in a New Hampshire speech that was part policy roll out and part political rally.
Notable weakness is coming from the FANG leadership group, which is being weighed down by heavy losses in Facebook.
Brent Saunders spoke at the Barclays healthcare conference, a few weeks after Mylan and Revance Therapeutics said they were teaming up on a proposed biosimilar of Allergan's Botox.
We still believe that the overhang that limited Broadcom stock's lift over the last few months has been removed.
A study published by the Journal of the American Medical Association shows OTC drugs were more effective in cutting pain for chronic back pain and osteoarthritis hip and knee patients than opioids.
Our strategy here is to have a wait and see approach and pick our spots.
Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.
WEIR JOINED COOLSCULPTING EXECUTIVES AND NEW YORK CITY DOCTOR TO DISCUSS THE #1 NON-SURGICAL BODY SCULPTING PROCEDURE
John Ferriola, chairman, president and CEO of Nucor, tells Jim Cramer about the U.S. steel industry and the impact of tariffs.
Jim Cramer focuses on Kinder Morgan, Blackberry, CVS Health, AK Steel Holdings, Capital One Financial, AeroVironment, and Intuitive Surgical.
Patrick Doyle, president and CEO of Domino's Pizza, tells Jim Cramer the company is celebrating its 15,000th location around the globe.
Despite everyone's worries, and all the bearish predictions, Beijing wants a trade war even less than we do, says Jim Cramer.
This is the exact type of strength we are looking for and recoups some of the cash we used earlier this morning.
We initiated a position in 3M, exited GE, and downgraded two ratings to Three last week.
Mylan and Revance Therapeutics say they have teamed up to develop and commercialize a proposed biosimilar or copy of Allergan's popular Botox, potentially ratcheting up pressure on the drugmaker.
The pharmaceutical company unveiled a collaboration and license pact with Revance Therapeutics to develop and commercialize a proposed biosimilar or copy of Allergan's Botox.
Nucor looks to gain on the expected tariffs announcement, while separately we're downgrading Allergan.
Jim discusses Amazon's recent acquisition, the industrials, and other news around the market.
After months of inaction by the federal government on the crisis regarding opioid abuse, Attorney General Jeff Sessions announced the creation of a task force charged with looking at how drug makers and distributors operate.
Jim Cramer focuses on STMicroelectronics, PetMed Express, Lumentum Holdings, and Allergan.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.